Market Research Future provides premium research reports that are relevant across all sectors. Recently published “Epigenetics Market Research Report – Forecast to 2023” provides analysis of factors pertinent to market growth. Expert data analysts take a magnifying glass to the various nuances of the market in an effort to impart put forth fresh content which is vital in assisting organizations to make major business decisions
Key Vendors Operating In the Global Epigenetics Market:
Bio-Rad (US), Illumina (US), QIAGEN (Netherlands), Thermo Fisher (US), Active Motif (US), Diagenode (Belgium), Agilent (US), Merck Millipore (US), Abcam (UK), New England Biolabs (US), PerkinElmer (US), Zymo Research (US), and others.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6161 .
Epigenetics is the study of heritable changes in gene function not involving changes in the DNA sequence such as changes in a chromosome, phenotypic affecting gene activity and expression. The sources of heritable changes may be external from environmental factors, or internal factors such as age, disease and others. Examples of Epigenetics are DNA methylation and histone modification, which alters genes expression without altering the DNA sequence.
The market drivers of Epigenetics are growing risk factors and the associated increase in cases of cancer, increase in the R&D activities, developing pharmaceutical, and biotechnology sectors, application expanse of epigenetics and others. The development of high sensitive and selective tests, instrumentation and a concurrent rise in computational power is driving a massive adoption. The advancements such as the development of DNA and RNA modifying enzymes such as acetylases, methyltransferases, reverse transcriptase, ligases, and other protein-modifying enzymes has generated tremendous enthusiasm and concurrent faster market adoption.
The growing government support for biotechnology and growing partnership between academia and industry is another driver of growth. Attractive and critical advantages of technology exemplified by high-throughput molecular analysis of tissues, such as quick, cost-effective, efficient for less labor intensive and requires a lesser number of steps are the operational and economic driving factors of the market. Other technological developments include automation, advances in PCR technology, strategic and cross-functional nature of the molecular diagnostic technology and others.
High growth of biotech and growing number of start-ups are driving the development of proprietary technology. According to national venture capital association, the Biotechnology industry received the second largest amount of venture capital for the year 2016 and ended with a 17% rise in dollars as compared with the previous year.
The prime market constraints include prohibitive costs of molecular diagnostics, ha high cost of manufacturing, consolidated nature of the market has put a premium on the price other f the epigenetics products, nascent stage of technology and high power of firms relative to buyers.
The Global Epigenetics Market is segmented based on instruments, consumables, applications, technology, end users, and regions.
Based on instruments, the market comprises of NGS, spectrometer, PCR, software solutions and others.
Based on consumables, the market comprises of kit, enzymes, reagent, and others.
Based on application, the market comprises of oncology, developmental biology, drug discovery, cardiology, immunology, and others.
Based on technology, the market comprises of methylation, histone modification, and others.
Based on end users the market is segmented into academia and research, pharmaceutical and biotechnology industry and others.
Based on the regions, the market is segmented as North America, Europe, Asia Pacific Middle East and Africa and rest of the world.
Get Quality Discount @ https://www.marketresearchfuture.com/check-discount/6161 .
North America is the largest market in 2016 with the U.S. in the lead position owing to the faster uptake of technology, the gigantic biotech industry of the U.S., the presence of global and technology players, which is propelling the molecular diagnostics industry.
Europe led by Germany, U.K., and France accounts for the second-largest and second fastest market during the forecasted period. Asia is anticipated to expand at the most rapid rate led by Japan, China, South Korea and India.
The Middle East and Africa market are anticipated to generate a moderate growth on account of the impoverished industry landscape and low demand due to weak economic conditions.